ReBiA-Robotic Enabled Biological Automation: 3D Epithelial Tissue Production.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
PMID:

Abstract

The Food and Drug Administration's recent decision to eliminate mandatory animal testing for drug approval marks a significant shift to alternative methods. Similarly, the European Parliament is advocating for a faster transition, reflecting public preference for animal-free research practices. In vitro tissue models are increasingly recognized as valuable tools for regulatory assessments before clinical trials, in line with the 3R principles (Replace, Reduce, Refine). Despite their potential, barriers such as the need for standardization, availability, and cost hinder their widespread adoption. To address these challenges, the Robotic Enabled Biological Automation (ReBiA) system is developed. This system uses a dual-arm robot capable of standardizing laboratory processes within a closed automated environment, translating manual processes into automated ones. This reduces the need for process-specific developments, making in vitro tissue models more consistent and cost-effective. ReBiA's performance is demonstrated through producing human reconstructed epidermis, human airway epithelial models, and human intestinal organoids. Analyses confirm that these models match the morphology and protein expression of manually prepared and native tissues, with similar cell viability. These successes highlight ReBiA's potential to lower barriers to broader adoption of in vitro tissue models, supporting a shift toward more ethical and advanced research methods.

Authors

  • Lukas Königer
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Christoph Malkmus
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Dalia Mahdy
  • Thomas Däullary
    Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070, Würzburg, Germany.
  • Susanna Götz
    Faculty of Design Würzburg, Technical University of Applied Sciences Würzburg-Schweinfurt, 97070, Würzburg, Germany.
  • Thomas Schwarz
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Marius Gensler
    Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070, Würzburg, Germany.
  • Niklas Pallmann
    Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070, Würzburg, Germany.
  • Danjouma Cheufou
    Klinik für Thoraxchirurgie, Klinikum Würzburg Mitte gGmbH, Deutschland.
  • Andreas Rosenwald
    Institute of Pathology, University of Würzburg, 97080, Würzburg, Germany.
  • Marc Möllmann
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Dieter Groneberg
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Christina Popp
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Florian Groeber-Becker
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Maria Steinke
    Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research ISC, 97070, Würzburg, Germany.
  • Jan Hansmann
    University of Applied Sciences Würzburg-Schweinfurt, Schweinfurt.